Joseph Vazzano Biography and Net Worth

Mr. Vazzano has served as our Chief Financial Officer (CFO) since February 2019.  Prior to CFO, Mr. Vazzano was Avenue’s Vice President of Finance and Corporate Controller (principal financial and accounting officer) since July 2017.  Mr. Vazzano joined Avenue from Intercept Pharmaceuticals, Inc., where he served as Assistant Corporate Controller and oversaw the expansion of the company’s finance and accounting department during its transition from development-stage to a fully integrated commercial organization. Prior to Intercept, Mr. Vazzano served as Assistant Controller at Pernix Therapeutics, where he successfully built an accounting and finance team after a corporate restructuring. Earlier in his career, Mr. Vazzano held roles of increasing responsibility in finance and accounting at NPS Pharmaceuticals, a publicly traded biotechnology company acquired by Shire Pharmaceuticals, and was a senior auditor at KPMG, LLP. Mr. Vazzano holds a B.S. in accounting from Lehigh University in Bethlehem, PA, and is a certified public accountant in New Jersey.

What is Joseph Walter Vazzano's net worth?

The estimated net worth of Joseph Walter Vazzano is at least $293,634.00 as of September 15th, 2021. Mr. Vazzano owns 65,252 shares of Avenue Therapeutics stock worth more than $293,634 as of September 26th. This net worth approximation does not reflect any other investments that Mr. Vazzano may own. Learn More about Joseph Walter Vazzano's net worth.

What is Joseph Walter Vazzano's salary?

As the CFO of Avenue Therapeutics, Inc., Mr. Vazzano earned a total compensation package of $214,890.00 in 2020. Mr. Vazzano earned a salary of $206,000.00, and other compensation of $8,890.00. Learn More on Joseph Walter Vazzano's salary.

How do I contact Joseph Walter Vazzano?

The corporate mailing address for Mr. Vazzano and other Avenue Therapeutics executives is 1140 Avenue of the Americas Floor 9, NEW YORK NY, 10036. Avenue Therapeutics can also be reached via phone at (781) 652-4500 and via email at [email protected] Learn More on Joseph Walter Vazzano's contact information.

Has Joseph Walter Vazzano been buying or selling shares of Avenue Therapeutics?

Joseph Walter Vazzano has not been actively trading shares of Avenue Therapeutics in the last ninety days. Most recently, Joseph Walter Vazzano sold 7,160 shares of the business's stock in a transaction on Wednesday, September 15th. The shares were sold at an average price of $1.62, for a transaction totalling $11,599.20. Following the completion of the sale, the chief financial officer now directly owns 65,252 shares of the company's stock, valued at $105,708.24. Learn More on Joseph Walter Vazzano's trading history.

Who are Avenue Therapeutics' active insiders?

Avenue Therapeutics' insider roster includes Neil Herskowitz (Director), and Joseph Vazzano (CFO). Learn More on Avenue Therapeutics' active insiders.

Joseph Walter Vazzano Insider Trading History at Avenue Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/15/2021Sell7,160$1.62$11,599.2065,252View SEC Filing Icon  
3/9/2020Buy1,500$7.99$11,985.0059,263View SEC Filing Icon  
8/9/2019Sell4,688$5.59$26,205.9259,038View SEC Filing Icon  
See Full Table

Joseph Walter Vazzano Buying and Selling Activity at Avenue Therapeutics

This chart shows Joseph Walter Vazzano's buying and selling at Avenue Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Avenue Therapeutics Company Overview

Avenue Therapeutics logo
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
Read More

Today's Range

Now: $4.50
Low: $3.62
High: $6.35

50 Day Range

MA: $5.29
Low: $3.21
High: $67.50

2 Week Range

Now: $4.50
Low: $3.00
High: $27.75


5,738,600 shs

Average Volume

202,834 shs

Market Capitalization

$98.95 million

P/E Ratio


Dividend Yield